Migraine

Researchers observed that migraine was associated with an increased risk of developing a cochlear disorder, especially tinnitus.

Recent data shows how common combination coprescribing of opioids with a triptan or a serotonergic antidepressant was just 2 years prior to an FDA warning about the risk of serotonin syndrome from such coprescribing.

The Institute for Clinical and Economic Review (ICER) has released their final evidence report evaluating the effectiveness and value of calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients who suffer from episodic or chronic migraine.

Through a smartphone app, SensorRx is utilizing patient-collected data and linking it to the patient’s electronic health record, allowing the physician to better understand a patient’s migraine trends and improve outcomes.

As researchers examined what food and drinks were most commonly linked to migraine and tension-type headache in Malaysian patients, they found that coffee and chocolate were reported most often.

According to Amgen and Novartis, their calcitonin gene-related peptide inhibitor has demonstrated safety and efficacy in a 1-year study in chronic migraine and reinforced safety and tolerability in a 3-year interim analysis from an ongoing 5-year study in episodic migraine.

While it is known that heightened estrogen levels are linked to an increased prevalence of migraine in women, new research suggests that the hormone plays an equally important role in causing migraine among men.

The average duration of a migraine was found to be independent from the presence of allergy, as well as the frequency of the cephalalgy attacks, and the localization of the pain.

For many patients with migraine, cannabis served as a substitute for other pain medications, including opioids.

This health economic analysis predicted that, compared with use of supportive care, erenumab treatment will reduce the direct and indirect costs associated with migraine and increase quality-adjusted life-years for patients who have previously experienced treatment failure with at least 1 preventive migraine treatment.

Employers that offer healthcare benefits, paid sick days, and disability insurance benefits will spend about $84,000 in annual migraine-related costs for every 1000 employees.

Despite behavioral migraine treatment being effective, safe, and well-tolerated, less than one-third of eligible patients are referred for treatment and only half of those referred initiate treatment.

While the pilot study successfully explored the efficacy of timolol eyedrops, further research is necessary to identify patients who would benefit the most from this treatment and an appropriate dosage.

The large-scale patient registry and biorepository includes patient information and biological samples and leverages machine learning to track the progress of patients over time.

Galcanezumab demonstrated clinically and statistically significant benefits across several migraine-relevant outcomes when compared to placebo.

Erenumab is the first calcitonin gene-related peptide (CGRP) inhibitor to be approved by the FDA for the prevention of migraine. The Institute for Clinical and Economic Review assessed the comparative effectiveness and value of erenumab with 2 other CGRP inhibitors that are still under FDA review.

Two studies presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting investigated the economic and clinical burdens on patients diagnosed with migraine.

Working age migraineurs are more likely to experience painful musculoskeletal disorders, such as fibromyalgia and depression, than those without migraine.

Two study abstracts presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, examined the prevalence of preventive and opioid treatment for migraine.